Got questions on Kerendia (finerenone)? Hear from Prof Eugenia Pedagogos

dr pedagogos

To request additional HCP & Patient resources, click here.

    What is the role of the GP in managing patients with CKD & T2D in the context of Kerendia (finerenone)? (02:17)

    How to initiate Kerendia (finerenone) (02:03)

    What is the safety profile of Kerendia (finerenone) in patients with T2D & CKD? (02:31)

    Which patients are suitable for Kerendia (finerenone) based on the PBS criteria? (01:02)

    If my patient is already on an SGLT2i, should I start them on finerenone? (02:10)

    What does a reduction in UACR mean for patients with CKD & T2D? (02:30)

    Key Take aways from Prof Eugenia Pedagogos (01:08)

PBS_Info_Kerendia_white_bkg

Please review the full product information before prescribing Kerendia (finerenone). Approved PI available here or upon request from Bayer Medical Information on 1800 008 757.
 

▼This medicinal product is subject to additional monitoring in Australia. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse events at  https://www.tga.gov.au/­report­-adverse­-event­-or­-problem­-health­-professionals.

PP-KER-AU-0546-1 Prepared July 2026